WO2012060675A1 - Procédé de préparation de rifaximine amorphe - Google Patents

Procédé de préparation de rifaximine amorphe Download PDF

Info

Publication number
WO2012060675A1
WO2012060675A1 PCT/MX2010/000123 MX2010000123W WO2012060675A1 WO 2012060675 A1 WO2012060675 A1 WO 2012060675A1 MX 2010000123 W MX2010000123 W MX 2010000123W WO 2012060675 A1 WO2012060675 A1 WO 2012060675A1
Authority
WO
WIPO (PCT)
Prior art keywords
rifaximin
demineralized water
amorphous
minutes
temperature
Prior art date
Application number
PCT/MX2010/000123
Other languages
English (en)
Spanish (es)
Inventor
Umberto Bruno Casazza
Aaron RODRÍGUEZ WELTON
Original Assignee
Interquim, S.A. De C.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interquim, S.A. De C.V. filed Critical Interquim, S.A. De C.V.
Priority to PCT/MX2010/000123 priority Critical patent/WO2012060675A1/fr
Publication of WO2012060675A1 publication Critical patent/WO2012060675A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Definitions

  • This invention relates to a process of preparing rifaximin in a stable amorphous form.
  • Rifaximin is a bactericidal antibiotic molecule, with a broad spectrum of action on Gram-positive and Gram-negative bacteria, both aerobic and anaerobic. Its absorption in the gastrointestinal tract is practically nil (less than 1%), which favors the concentration of the drug in the intestinal lumen and, especially, in the feces in active form.
  • Rifaximin is a semi-synthetic antibiotic, derived from rifamycin.
  • the introduction of a pyridoimidazole group in the basic structure of rifamycins makes this antibiotic practically not absorbed through the digestive tract.
  • GB 2,079,270 discloses imidazo-rifamycin derivatives that have antibacterial activity, prepared from 3S-halo-rifamycin.
  • US Patent No. 4,341,785 and EP 0.161,534 describe the processes for preparing rifaximin from pyridoimidazole rifamycin O.
  • the above patents detail a generic method for purification of rifaximin in convenient solvent systems such as chloride of methylene, chloroform, methanol, ethanol, isopropanol. Water is generally used as an anti-solvent.
  • the polymorphic form of rifaximin obtained by these methods was not disclosed. Recently, three polymorphic forms of Rifaximin were described in Ü.SA Patent No.
  • 7,045,620 identified as ⁇ , ⁇ , and y.
  • the point of differentiation between these forms is their water content and respective diffraction X-ray diffraction (dust) ⁇ PXRD).
  • dust diffraction X-ray diffraction
  • PXRD diffraction X-ray diffraction
  • These forms are interchangeable and, therefore, obtaining a specific polymorphic form is dependent on the drying conditions.
  • the form and mentioned in US Patent No. 7,045,620 is described as a non-crystalline form with a high content of the amorphous component. It is characterized by having a water content between 1.0% and 2.0% and having a PXRD diffractometer with some significant peaks at 5.0, 7.1 and 8.4 (two-theta). Particularly, this form is prepared by dissolving in ethanol followed by the addition of water.
  • RIFAXYMIN POLYMORPHIC FORMS AS ANTIBIOTICS polymorphic crystalline forms of the antibiotic rifaximin (INN) called rifaximin ⁇ and rifaximin ⁇ are disclosed, a poorly crystalline form called rifaximin and.
  • the present invention aims to prepare Rifaximin in its amorphous form by handling the original basic pH of the reaction between Rifamycin O and 2-Amino-4-methylpyridine and its purification with Ethanol.
  • Still another object of the present invention is to effect the conversion of the crystalline form ⁇ , ⁇ or ⁇ to the amorphous form by the change of acidic to basic pH confirming that the crystal form does not depend on the moisture content.
  • the object of the present invention to disclose a stable amorphous form of rifaximin.
  • the stable amorphous form of rifaximin is characterized by having peaks of the X-ray powder diffraction pattern, as illustrated in fig. 1, expressed in Intensity vs 28 / degree.
  • the present invention demonstrates that amorphous Rifaximin can be obtained independently of the moisture content, and that said form depends on the basic pH. As well as the fact that it is possible to convert the crystalline form ⁇ , ⁇ or ⁇ to the form amorphous by the change of acidic pH to basic confirming that the shape of the crystal does not depend on the moisture content.
  • this form is chemically and polymorphically stable and is relatively unaffected by external parameters such as; Ambient humidity
  • Ambient humidity For example, exposure of the amorphous form of the present invention to ambient humidity for a period of 10 days did not change the polymorphic form as indicated by the PXRD analyzes.
  • the high production of the amorphous form of rifaximin is obtained with the processes of the present invention and has high chemical purity.
  • the present invention provides a process for the preparation of the stable amorphous form of rifaximin comprising:
  • Fig. 1 illustrates the X-ray diffractometer
  • Fig. 2 and 3 illustrate the X-ray diffractometers (powders) of Rifaximins with the amorphous form
  • Fig. 4 and 5 illustrate the X-ray diffractogram (powders) of Rifaximins in the amorphous form of pilot batches.
  • Fig. 6 illustrates the X-ray diffractogram (powders) of Rifaximin in the amorphous form of a recovery lot.
  • Fig. 7 and 8 illustrate the Dif X-ray actomegrams (powders) of Rifaximin with the amorphous form (to these Rifaximins the conversion of ⁇ crystal to amorphous form was performed).
  • Amorphous rifaximin is obtained by adding a mixture of demineralized water, potable ethanol and acetone, rifamycin O and 2-Amino-4-methylpyridine, at pH 9.0 to 9.5, stir at a temperature of 23-27 ° C for 22 hours. Cool the reaction mixture to 5-10 ° C and keep at this temperature for 30 minutes.
  • Raw amorphous rifaximin is purified by adding a mixture of anhydrous ethanol and potable ethanol, 1: 1, raw amorphous Rifaximin. This suspension is heated at 40 +/- 2 ° C, with stirring and maintained at this temperature for 3 hours. It is cooled to 10 + 1 ° C and maintained for 30 minutes at this temperature. Filter and wash with a drinkable Ethanol / Demineralized Water (1: 1) mixture.
  • Rifaximin was dissolved in any of its crystalline forms in Acetone, and subsequent addition of demineralized Water, using the pH at 9.5 with an alkaline Hydroxide solution sodium, potassium hydroxide, sodium carbonate, ammonium hydroxide or similar base.
  • This amorphous Rifaximin was also identified and characterized by the X-ray diffraction technique.
  • DRIFA-570908 C2 samples; DRIFA-720910 RIFA- 50022002 and RIFA- 002100: 6 were analyzed at the Institute of Physics, ÜNAM, Crystal Structures Refining Laboratory, on a BRüJKER D8 ADVANCE diffractometer, using Ka radiation Cu; at 40kV, 30mA; under the following conditions: from 2 to 40 ° 2 ⁇ , at 0.01945 ° (2 ⁇ ) / 81 seconds in 16:21 minutes.
  • Amorphous Rifaximin was identified and characterized by the X-ray diffraction technique (powders).
  • amorphous Rifaximin depends on the pH value (7.5-10.5) in the reaction solution and that it does not depend on the humidity (KF) at which it is found, for this work was carried out in a humidity range (KF) from 0.5 to 5.0%.
  • Example 1 illustrate the best way to put the present invention into practice, without necessarily being limiting, since since a technician with average knowledge in the field will be able to deduce other modalities which are also part of the present invention: Example 1.
  • the pH is adjusted to 9.4-9.6 with concentrated ammonium hydroxide.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé d'obtention de rifaximine sous sa forme amorphe par manipulation du pH basique original de la réaction entre la rifamicine O et la 2-amino-4-méthylpyridine et sa purification avec de l'éthanol. On démontre ainsi que la rifaximine obtenue de cette manière ne dépend pas de la teneur en humidité pour déterminer sa forme cristalline, mais varie en fonction du pH. Par ailleurs, on réalise la conversion de la forme cristalline α, β ou γ à la forme amorphe par changement du pH d'une valeur acide à une valeur basique, ce qui confirme que la forme du cristal ne dépend pas de la teneur en humidité.
PCT/MX2010/000123 2010-11-05 2010-11-05 Procédé de préparation de rifaximine amorphe WO2012060675A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/MX2010/000123 WO2012060675A1 (fr) 2010-11-05 2010-11-05 Procédé de préparation de rifaximine amorphe

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2010/000123 WO2012060675A1 (fr) 2010-11-05 2010-11-05 Procédé de préparation de rifaximine amorphe

Publications (1)

Publication Number Publication Date
WO2012060675A1 true WO2012060675A1 (fr) 2012-05-10

Family

ID=46024646

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2010/000123 WO2012060675A1 (fr) 2010-11-05 2010-11-05 Procédé de préparation de rifaximine amorphe

Country Status (1)

Country Link
WO (1) WO2012060675A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9234872B2 (en) 2009-11-23 2016-01-12 California Institute Of Technology Chemical sensing and/or measuring devices and methods
US9938298B2 (en) 2014-05-12 2018-04-10 Alfa Wassermann S.P.A. Solvated crystal form of rifaximin, production, compositions and uses thereof
US10556915B2 (en) 2014-03-31 2020-02-11 Euticals Spa Polymorphic mixture of Rifaximin and its use for the preparation of solid formulations
US10703763B2 (en) 2005-03-03 2020-07-07 Alfasigma S.P.A. Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044823A2 (fr) * 2003-11-07 2005-05-19 Alfa Wassermann S.P.A. Formes polymorphes de rifaximine, leurs precedes de production, et leur utilisation dans des preparations medicinales
WO2008035109A1 (fr) * 2006-09-22 2008-03-27 Cipla Limited Rifaximine
WO2008155728A1 (fr) * 2007-06-20 2008-12-24 Solmag S.P.A. Procédé de préparation de rifaximine amorphe et la rifaximine amorphe ainsi obtenue

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044823A2 (fr) * 2003-11-07 2005-05-19 Alfa Wassermann S.P.A. Formes polymorphes de rifaximine, leurs precedes de production, et leur utilisation dans des preparations medicinales
WO2008035109A1 (fr) * 2006-09-22 2008-03-27 Cipla Limited Rifaximine
WO2008155728A1 (fr) * 2007-06-20 2008-12-24 Solmag S.P.A. Procédé de préparation de rifaximine amorphe et la rifaximine amorphe ainsi obtenue

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10703763B2 (en) 2005-03-03 2020-07-07 Alfasigma S.P.A. Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US9234872B2 (en) 2009-11-23 2016-01-12 California Institute Of Technology Chemical sensing and/or measuring devices and methods
US10556915B2 (en) 2014-03-31 2020-02-11 Euticals Spa Polymorphic mixture of Rifaximin and its use for the preparation of solid formulations
US10745415B2 (en) 2014-03-31 2020-08-18 Amri Italy S.R.L. Polymorphic mixture of Rifaximin and its use for the preparation of solid formulations
US10961257B2 (en) 2014-03-31 2021-03-30 Amri Italy S.R.L. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
US11739099B2 (en) 2014-03-31 2023-08-29 Curia Ip Holdings, Llc Polymorphic mixture of Rifaximin and its use for the preparation of solid formulations
US9938298B2 (en) 2014-05-12 2018-04-10 Alfa Wassermann S.P.A. Solvated crystal form of rifaximin, production, compositions and uses thereof
US10428086B2 (en) 2014-05-12 2019-10-01 Alfasigma S.P.A. Solvated crystal form of rifaximin, production, compositions and uses thereof

Similar Documents

Publication Publication Date Title
US10501422B2 (en) Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
ES2952770T3 (es) Formas de estado sólido de apalutamida
WO2007010555A2 (fr) Nouvelles formes cristallines d'hydrochlorure de moxifloxacine et procede de preparation associe
AR043547A1 (es) Formas polimorficas de rifaximina, procesos para su produccion y uso de las mismas en preparaciones medicinales
TR201802636T4 (tr) Bi̇r plöromuti̇li̇n' i̇n (plöromuti̇li̇n) kri̇stali̇n formu.
EP3406619B1 (fr) Procédé et intermédiaire pour la préparation de la tulathromycine
WO2012060675A1 (fr) Procédé de préparation de rifaximine amorphe
WO2004104010A1 (fr) Forme cristalline de cefdinir
ZA200300472B (en) Process for the preparation of highly pure crystalline (R,S)-cefuroxime axetil.
ES2319125T3 (es) Polimorfos del clorhidrato del acido 1-ciclopropil-7-((s,s)-2,8-diazadiciclo(4.3.0)-non-8-il)-6-fluoro-1,4-dihidro-8-metoxi-4-oxo-3-quinolina carboxilico y metodos para la preparacion de los mismos.
ES2394688T3 (es) Fase precursora y su utilización para preparar la sal de magnesio tetrahidratada de un enantiómero del omeprazol
WO2007008672A1 (fr) Cefdinir trihemihydrate cristallin
CN104277053B (zh) 一种头孢地嗪及其中间体头孢地嗪酸的制备方法
US20080221076A1 (en) Crystalline Sodium Salt of Cephalosporin Antibiotic
CN105440054B (zh) 一种制备头孢硫脒的工艺
EP0547646B1 (fr) Forme cristalline d'une céphalosporine antibiotique
US8765684B2 (en) Solid materials of {[(2S,5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid} and methods for obtaining them
CN110256464B (zh) 头孢妥仑匹酯开环二聚体的制备方法
SI21270A (sl) Kristalne oblike olanzapina in postopki za njihovo pripravo
US9637502B2 (en) Crystal form of Cefathiamidine compound and preparation method therefor
CN105622635B (zh) 一种减少过敏反应的头孢唑肟钠新晶型及其制剂
ES2312650T3 (es) Nuevo derivado de triazolobenzazepina triciclica cristalina.
CN103102358A (zh) 一种头孢类化合物、其晶体及其制备方法和用途
CN104844626A (zh) 头孢孟多酯钠的新晶型及其结晶制备方法
CN102633774B (zh) 蛋氨酸或氧化蛋氨酸修饰的克林沙星及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10859319

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/005679

Country of ref document: MX

122 Ep: pct application non-entry in european phase

Ref document number: 10859319

Country of ref document: EP

Kind code of ref document: A1